Skip to main content

Advertisement

SpringerLink
Log in

Rationale for statins in the chemoprevention of prostate cancer

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

The potential ability of statin medications to prevent cancer has recently received considerable attention. Of all cancers studied, data for prostate cancer are the most promising. Results from studies examining the association between statin use and reduced risk of prostate cancer have been encouraging, particularly in terms of advanced prostate cancer risk. These findings are supported by a strong foundation of scientific evidence demonstrating the potential cholesterol and non-cholesterol-mediated mechanisms through which statins may prevent prostate cancer. In this article, we analyze recent human data regarding the association between statins and prostate cancer, and the basic scientific data supporting the possible antineoplastic mechanisms of statins. We also address the issue of where to best direct future funding and research energies. There is currently insufficient evidence to recommend all men to initiate therapy with a statin medication regardless of cholesterol profile, but the rationale to move forward with research is clear.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Lamb E: Top 200 Prescription Drugs of 2006. Pharmacy Times, May 2007. Accessible at http://www.pharmacy-times.com/article.cfm?ID=4629. Accessed December 2007.

  2. Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267–1278.

    Article  PubMed  CAS  Google Scholar 

  3. Poynter JN, Gruber SB, Higgins PD, et al.: Statins and the risk of colorectal cancer. N Engl J Med 2005, 352:2184–2192.

    Article  PubMed  CAS  Google Scholar 

  4. Friis S, Poulsen AH, Johnsen SP, et al.: Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005, 114:643–647.

    Article  PubMed  CAS  Google Scholar 

  5. Shannon J, Tewoderos S, Garzotto M, et al.: Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005, 162:318–325.

    Article  PubMed  Google Scholar 

  6. Graaf MR, Beiderbeck AB, Egberts AC, et al.: The risk of cancer in users of statins. J Clin Oncol 2004, 22:2388–2394.

    Article  PubMed  CAS  Google Scholar 

  7. Platz EA, Leitzmann MF, Visvanathan K, et al.: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006, 98:1819–1825.

    Article  PubMed  CAS  Google Scholar 

  8. Jacobs EJ, Rodriguez C, Bain EB, et al.: Cholesterol-lowering drugs and advanced prostate cancer incidence in a large US cohort. Cancer Epidemiol Biomarkers Prev 2007, 16:2213–2217.

    Article  PubMed  CAS  Google Scholar 

  9. Flick ED, Habel LA, Chan KA, et al.: Statin use and risk of prostate cancer in the California Men’s Health Study Cohort. Cancer Epidemiol Biomarkers Prev 2007, 16:2218–2225.

    Article  PubMed  CAS  Google Scholar 

  10. Murtola T, Tammela TLJ, Lahtela J, Auvinen A: Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007, 16:2226–2232.

    Article  PubMed  CAS  Google Scholar 

  11. Murtola TJ, Tammela TLJ, Maattanen L, Auvinen A: Statins and prostate cancer among men participating in the Finnish Prostate Cancer Screening Trial [abstract 1719]. Proceedings of the American Urological Association Meeting. Anaheim, CA; May 19–24, 2007.

  12. Dale KM, Coleman CI, Henyan NN, et al.: Statins and cancer risk: a meta-analysis. JAMA 2006, 295:74–80.

    Article  PubMed  CAS  Google Scholar 

  13. Browning DR, Martin RM: Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007, 120:833–843.

    Article  PubMed  CAS  Google Scholar 

  14. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990, 343:425–430.

    Article  PubMed  CAS  Google Scholar 

  15. Rosenson RS: Current overview of statin-induced myopathy. Am J Med 2004, 116:408–416.

    Article  PubMed  CAS  Google Scholar 

  16. Kashani A, Phillips CO, Foody JM, et al.: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114:2788–2797.

    Article  PubMed  CAS  Google Scholar 

  17. Siegel D, Lopez J, Meier J: Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med 2000, 108:496–499.

    Article  PubMed  CAS  Google Scholar 

  18. LaRosa JC: Pleiotropic effects of statins and their clinical significance. Am J Cardiol 2001, 88:291–293.

    Article  PubMed  CAS  Google Scholar 

  19. Thompson IM, Goodman PJ, Tangen CM et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215–224.

    Article  PubMed  CAS  Google Scholar 

  20. Blais L, Desgagne A, LeLorier J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000, 160:2363–2368.

    Article  PubMed  CAS  Google Scholar 

  21. Coogan PF, Rosenberg L, Strom BL: Statin use and the risk of 10 cancers. Epidemiology 2007, 18:213–219.

    Article  PubMed  Google Scholar 

  22. Kaye JA, Jick H: Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004, 90:635–637.

    Article  PubMed  CAS  Google Scholar 

  23. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D: The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 2005, 173:1923–1925.

    Article  PubMed  CAS  Google Scholar 

  24. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ: The influence of statin medications on prostate specific antigen levels in healthy men [abstract 463]. Proceedings of the American Urological Association Annual Meeting. Anaheim, CA; May 19–24, 2007. Accessible at http://www.abstracts2view.com/aua/index.php.

  25. Ciatto S, Zappa M, Villers A, et al.: Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU Int 2003, 92(Suppl 2):97–100.

    Article  PubMed  Google Scholar 

  26. Youssef S, Stuve O, Patarroyo JC, et al.: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78–84.

    Article  PubMed  CAS  Google Scholar 

  27. Weis M, Heeschen C, Glassford AJ, Cooke JP: Statins have biphasic effects on angiogenesis. Circulation 2002, 105:739–745.

    Article  PubMed  CAS  Google Scholar 

  28. Rao S, Porter DC, Chen X, et al.: Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A 1999, 96:7797–7802.

    Article  PubMed  CAS  Google Scholar 

  29. Nubel T, Dippold W, Kleinert H, et al.: Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. Faseb J 2004, 18:140–142.

    PubMed  CAS  Google Scholar 

  30. Kusama T, Mukai M, Iwasaki T, et al.: Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 2001, 61:4885–4891.

    PubMed  CAS  Google Scholar 

  31. Marcelli M, Cunningham GR, Haidacher SJ, et al.: Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 1998, 58:76–83.

    PubMed  CAS  Google Scholar 

  32. Wong WW, Tan MM, Xia Z, et al.: Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 2001, 7:2067–2075.

    PubMed  CAS  Google Scholar 

  33. Demierre MF, Higgins PD, Gruber SB, et al.: Statins and cancer prevention. Nat Rev Cancer 2005, 5:930–942.

    Article  PubMed  CAS  Google Scholar 

  34. Schaffner CP: Prostatic cholesterol metabolism: regulation and alteration. Prog Clin Biol Res 1981, 75A:279–324.

    PubMed  CAS  Google Scholar 

  35. Nelson PS, Clegg N, Arnold H, et al.: The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A 2002, 99:11890–11895.

    Article  PubMed  CAS  Google Scholar 

  36. Swinnen JV, Van Veldhoven PP, Esquenet M, et al.: Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 1996, 137:4468–4474.

    Article  PubMed  CAS  Google Scholar 

  37. Simons K, Ikonen E: Functional rafts in cell membranes. Nature 1997, 387:569–572.

    Article  PubMed  CAS  Google Scholar 

  38. Hager MH, Solomon KR, Freeman MR: The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care 2006, 9:379–385.

    Article  PubMed  CAS  Google Scholar 

  39. Freeman MR, Cinar B, Lu ML: Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab 2005, 16:273–279.

    Article  PubMed  CAS  Google Scholar 

  40. Zhuang L, Lin J, Lu ML, et al.: Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 2002, 62:2227–2231.

    PubMed  CAS  Google Scholar 

  41. Smith SM, Lei Y, Liu J, et al.: Luteinizing hormone receptors translocate to plasma membrane microdomains after binding of human chorionic gonadotropin. Endocrinology 2006, 147:1789–1795.

    Article  PubMed  CAS  Google Scholar 

  42. Lawrence JC, Saslowsky DE, Edwardson JM, Henderson RM: Real-time analysis of the effects of cholesterol on lipid raft behavior using atomic force microscopy. Biophys J 2003, 84:1827–1832.

    Article  PubMed  CAS  Google Scholar 

  43. El Sheikh SS, Domin J, Abel P, et al.: Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 2004, 6:846–853.

    Article  PubMed  CAS  Google Scholar 

  44. Horinaga M, Okita H, Nakashima J, et al.: Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. Urology 2005, 66:671–675.

    Article  PubMed  Google Scholar 

  45. Zhuang L, Kim J, Adam RM, et al.: Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005, 115:959–968.

    PubMed  CAS  Google Scholar 

  46. Dobs AS, Schrott H, Davidson MH, et al.: Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 2000, 49:1234–1238.

    Article  PubMed  CAS  Google Scholar 

  47. Smals AG, Weusten JJ, Benraad TJ, Kloppenborg PW: The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activity. J Steroid Biochem Mol Biol 1991, 38:465–468.

    Article  PubMed  CAS  Google Scholar 

  48. Segarra A, Chacon P, Vilardell M, Piera LL: Prospective case control study to determine the effect of lovastatin on serum testosterone and cortisol concentrations in hyperlipidemic nephrotic patients with chronic renal failure. Nephron 1996, 73:186–190.

    PubMed  CAS  Google Scholar 

  49. Bernini GP, Argenio GF, Gasperi M, et al.: Effects of long-term simvastatin treatment on testicular and adrenal steroidogenesis in hypercholesterolemic patients. J Endocrinol Invest 1994, 17:227–233.

    PubMed  CAS  Google Scholar 

  50. Bohm M, Herrmann W, Wassmann S, et al.: Does statin therapy influence steroid hormone synthesis? Z Kardiol 2004, 93:43–48.

    Article  PubMed  CAS  Google Scholar 

  51. Dobs AS, Miller S, Neri G, et al.: Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. Metabolism 2000, 49:115–121.

    Article  PubMed  CAS  Google Scholar 

  52. Hall SA, Page ST, Travison TG, et al.: Do statins affect androgen levels in men? Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev 2007, 16:1587–1594.

    Article  PubMed  CAS  Google Scholar 

  53. Page ST, Lin DW, Mostaghel EA, et al.: Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006, 91:3850–3856.

    Article  PubMed  CAS  Google Scholar 

  54. Pelletier G, Luu-The V, El-Alfy M, et al.: Immunoelectron microscopic localization of 3beta-hydroxysteroid dehydrogenase and type 5 17beta-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J Mol Endocrinol 2001, 26:11–19.

    Article  PubMed  CAS  Google Scholar 

  55. Heemers H, Vanderhoydonc F, Roskams T, et al.: Androgens stimulate coordinated lipogenic gene expression in normal target tissues in vivo. Mol Cell Endocrinol 2003, 205:21–31.

    Article  PubMed  CAS  Google Scholar 

  56. Eberle D, Hegarty B, Bossard P, et al.: SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004, 86:839–848.

    Article  PubMed  CAS  Google Scholar 

  57. Ettinger SL, Sobel R, Whitmore TG, et al.: Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 2004, 64:2212–2221.

    Article  PubMed  CAS  Google Scholar 

  58. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ: Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004, 30:609–641.

    Article  PubMed  CAS  Google Scholar 

  59. Weber MJ, Gioeli D: Ras signaling in prostate cancer progression. J Cell Biochem 2004, 91:13–25.

    Article  PubMed  CAS  Google Scholar 

  60. Lee SJ, Ha MJ, Lee J, et al.: Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem 1998, 273:10618–10623.

    Article  PubMed  CAS  Google Scholar 

  61. Moyad MA, Merrick GS, Butler WM, et al.: Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs 2006, 26:298–303.

    PubMed  Google Scholar 

  62. Shippy AM, Katz MS, Yamada Y, et al.: Statin use and clinical outcomes after high dose radiotherapy for prostate cancer [abstract 203]. Int J Radiat Biol 2007, 69:S113.

    Google Scholar 

  63. Hong SK, Han BK, Jeong SJ, et al.: Effect of statin therapy on early return of potency after nerve sparing radical retropubic prostatectomy. J Urol 2007, 178:613–616.

    Article  PubMed  Google Scholar 

  64. American Cancer Society. Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007.

    Google Scholar 

  65. Cox J, Clark S, Colli JL: Exploring causes for declining prostate cancer mortality rates in the United States between 1993 and 2003 [abstract 203]. Proceedings of the American Urological Association Meeting. Anaheim, CA; May 19–24, 2007.

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Duke University School of Medicine, Duke University Medical Center, Box 2626, Durham, NC, 27710, USA

    Stephen J. Freedland

Authors
  1. Robert J. Hamilton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen J. Freedland
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen J. Freedland.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hamilton, R.J., Freedland, S.J. Rationale for statins in the chemoprevention of prostate cancer. Curr Urol Rep 9, 189–196 (2008). https://doi.org/10.1007/s11934-008-0034-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-008-0034-z

Keywords

Search

Navigation